CN100339084C - Fosfocina calcium disperser, and its prepn. method - Google Patents
Fosfocina calcium disperser, and its prepn. method Download PDFInfo
- Publication number
- CN100339084C CN100339084C CNB2005101058918A CN200510105891A CN100339084C CN 100339084 C CN100339084 C CN 100339084C CN B2005101058918 A CNB2005101058918 A CN B2005101058918A CN 200510105891 A CN200510105891 A CN 200510105891A CN 100339084 C CN100339084 C CN 100339084C
- Authority
- CN
- China
- Prior art keywords
- calcium
- fosfomycin
- lactose
- microcrystalline cellulose
- magnesium stearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a fosfomycin calcium dispersing tablet and a preparation method thereof. The phosphomycin calcium dispersing tablet comprises phosphomycin calcium and a disintegrating agent. The phosphomycin calcium dispersing tablet is characterized in that the weight ratio of the phosphomycin calcium to the disintegrating agent is 10: 2 to 8, and preferably10: 4 to 8, wherein the disintegrating agent is selected from one or several kinds of crosslinked carboxymethyl cellulose natrium (cCMC-Na), natrium carboxymethyl starch (CM-Na), low-substituted hydroxypropyl cellulose (Ls-HPC), crosslinked polyethylene pyrrolidone (PVPP), microcrystalline cellulose (MCC) and pregelatine starch. The present invention is characterized in that the prepared dispersing tablet has the advantages of good dispersion state, short disintegration time, rapid medicine dissolution, rapid absorption, simple preparation process and stabile product quality.
Description
Technical field:
The present invention relates to a kind of dispersible tablet and preparation method thereof and medical usage of fosfomycin calcium, belong to medical technical field.
Background technology:
Fosfomycin calcium is recorded in two ones of Pharmacopoeia of People's Republic of China versions in 2005, chemistry (-) by name-(1R, 2S)-1,2-glycidyl phosphonic acids calcium salt monohydrate.Chemical structural formula is:
Fosfomycin calcium is a broad-spectrum sterilization medicine, and its antimicrobial spectrum is also more extensive than penicillin and cephalosporins.All effective to common gram positive bacteria, gram negative bacteria; Staphylococcus, escherichia coli, Serratieae, dysentery bacterium etc. there is higher antibacterial activity; Also effective to more drug-fast antibacterial such as bacillus pyocyaneus, the positive Bacillus proteus of indole, sonne bacillus, inflation bacillus, pneumobacillus etc.Fosfomycin calcium is oral to be used for the treatment of simple property lower urinary tract infection due to the sensitive organism and intestinal infection (comprising bacillary dysentery) etc., also can with other antimicrobial drug use in conjunction treatments by the severe infection due to the sensitive organism, as septicemia, peritonitis, osteomyelitis etc.Its mechanism of action is quite clear.
The nearly 30 years history of municipalization on the fosfomycin, China put into production in nineteen eighty-three, classified national essential drugs in 1993 as.From the statistics of nearest acquisition, its curative effect is similar substantially to the application initial stage.This product is mainly used in oral administration clinically, can treat intestinal infection, urinary tract infection, Helicobacter pylori infection and hordeolum, hordeolum, otitis media, nasal sinusitis, dacryocystisis etc.
Though fosfomycin calcium is an old medicine, some unique strong points are arranged, its chemical constitution uniqueness does not have cross resistance with other antibacterials, and tissue distribution is good, does not combine with serum albumin, and toxicity is low, no antigen.And the anti-enzyme of fosfomycin has good chemical stability.In numerous oral antibiotics, have broad-spectrum high efficacy, not by stomach acids destroy, and absorb the advantage of unable to take food thing influence.
Domestic patent (Granted publication number: described the fosfomycin calcium patent CN1160077C), it has disclosed the application and the external preparation thereof of fosfomycin calcium external aspect, its dosage form is ointment, gel, spray and granula subtilis, is mainly used in the healing of exterior trauma.Do not see the relevant patent report of Fosfocina calcium disperser agent and oral aspect.
The present fosfomycin calcium preparation of oral application clinically has tablet, capsule, granule and compound preparation, does not see the relevant report of its dispersible tablet.Because fosfomycin calcium slightly soluble in water, existing fosfomycin calcium oral formulations exists drug dissolution and bioavailability defect of bad; Simultaneously, since the day taking dose of fosfomycin calcium big (existing oral fosfomycin calcium preparation mixes with the adjuvant of more amount, so dosage form is bigger than normal usually the adult, is unfavorable for that the patient of old people, child, dysphagia takes in fosfomycin 2～4g) every day.
Summary of the invention:
The present invention is directed to the deficiency of the existing preparation of fosfomycin calcium, improve by dosage form, with preferred, be surprised to find that fosfomycin calcium and disintegrating agent pharmaceutically commonly used through the prescription design, according to specific mixed, make dispersible tablet, not only the sheet type diminishes, and has overcome the defective that existing fosfomycin calcium oral solid formulation exists, and, be surprisingly found out that Fosfocina calcium disperser medicine dissolution rate of the present invention is rapid, obviously improves bioavailability.
The present invention adopts following technical scheme:
Fosfocina calcium disperser of the present invention, comprise fosfomycin calcium and disintegrating agent, the weight ratio that it is characterized in that fosfomycin calcium and disintegrating agent is 10: 2～8, be preferably 10: 4～8, wherein said disintegrating agent is selected from one or more in cross-linking sodium carboxymethyl cellulose (cCMC-Na), carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (Ls-HPC), crospolyvinylpyrrolidone (PVPP), microcrystalline Cellulose (MCC), the pregelatinized Starch.
Above-mentioned described Fosfocina calcium disperser, wherein, the content of every middle fosfomycin is 50mg～1000mg, is preferably 100mg～500mg, more preferably 250mg.
Fosfocina calcium disperser of the present invention can also comprise binding agent, diluent, lubricant or correctives.Wherein binding agent is meant hydrophilic adhesive, is in polyvinylpyrrolidone (PVP), hydroxypropyl emthylcellulose (HPMC), starch slurry or the dextrin one or more; Diluent is one or more in lactose, mannitol, sorbitol, sucrose, microcrystalline Cellulose, starch or the dextrin; Lubricant is one or more in stearic acid, magnesium stearate, Polyethylene Glycol, micropowder silica gel or the Pulvis Talci; Correctives is one or more in lactose, aspartame or the saccharin sodium.
Preferably, Fosfocina calcium disperser of the present invention, fosfomycin calcium 2500g (pressing fosfomycin calculates), pregelatinized Starch 500g, lactose 350g, glue connection polyvinylpyrrolidone 300g, low-substituted hydroxypropyl cellulose 350g, magnesium stearate 50g as system soft material solution, makes 10000 with 40% alcoholic solution;
Perhaps, fosfomycin calcium 2500g (pressing fosfomycin calculates), lactose 200g, microcrystalline Cellulose (in add) 400g, microcrystalline Cellulose (adding) 400g, low-substituted hydroxypropyl cellulose 1200g, magnesium stearate 60g, aspartame 20g as system soft material solution, makes 10000 with 5% polyvinylpyrrolidone aqueous solution;
Perhaps, fosfomycin calcium 2500g (pressing fosfomycin calculates), lactose 750g, microcrystalline Cellulose 900g, crospolyvinylpyrrolidone 300g, magnesium stearate 55g as system soft material solution, makes 10000 with 5% polyvinylpyrrolidone aqueous solution;
Perhaps, fosfomycin calcium 2500g (pressing fosfomycin calculates), lactose 300g, microcrystalline Cellulose 380g, low-substituted hydroxypropyl cellulose 760g, crospolyvinylpyrrolidone 300g, magnesium stearate 55g as system soft material solution, makes 10000 with 5% polyvinylpyrrolidone aqueous solution;
Perhaps, fosfomycin calcium 2500g (pressing fosfomycin calculates), lactose 200g, microcrystalline Cellulose 1300g, carboxymethyl starch sodium 400g, aspartame 20g, magnesium stearate 55g as system soft material solution, makes 10000 with 40% alcoholic solution.
Fosfocina calcium disperser of the present invention can prepare by the following method, and it comprises the steps:
(1) gets the fosfomycin calcium of recipe quantity and the adjuvant of recipe quantity, mix homogeneously;
(2) wet granulation is crossed 18～20 mesh sieves, and 60 ℃～75 ℃ dryings of wet granular are with 18～20 mesh sieve granulate;
What (3) dried granule added recipe quantity adds disintegrating agent, lubricant, mix homogeneously;
(4) tabletting, control tablet weight variation limit is ± 5%.
Fosfocina calcium disperser of the present invention can be used for treating diseases such as intestinal infection, urinary tract infection, Helicobacter pylori infection, hordeolum, hordeolum, otitis media, nasal sinusitis or dacryocystisis.
Compare with existing fosfomycin calcium preparation, excellent results of the present invention is as follows:
(1) Fosfocina calcium disperser of the present invention, oral after rapidly disintegrate become homodisperse fine particle, the rapid stripping of medicine, dissolution rate is fast, helps improving bioavailability of medicament.
(2) Fosfocina calcium disperser of the present invention is compared with the fosfomycin calcium ordinary preparation, has obviously improved stability of drug, and has combined the advantage of tablet and solution, and avoided its shortcoming.
(3) instructions of taking variation, dispersible tablet can directly be swallowed, and also can add after the aqueous dispersion orally, also can be contained in and chew in the mouth or suck clothes, takes more convenient.
Description of drawings
Fig. 1: be product of the present invention and commercially available sample accumulation stripping curve figure
The specific embodiment:
Further specify the present invention by the following examples, but the claim protection domain is not limited to the scope of embodiment.
Embodiment 1
Prescription:
Fosfomycin calcium 2500g (by fosfomycin)
Pregelatinized Starch 500g
Lactose 350g
Crospolyvinylpyrrolidone 300g
Low-substituted hydroxypropyl cellulose 350g
40% alcoholic solution is an amount of
Magnesium stearate 50g
Make 10000
Preparation method:
1) get fosfomycin calcium and each adjuvant, cross 100 mesh sieves respectively, standby;
2) get the fosfomycin calcium of recipe quantity, mix with pregelatinized Starch, lactose, the crospolyvinylpyrrolidone of recipe quantity;
3) with 40% ethanol system soft material, cross 20 mesh sieves and granulate, put drying in 70 ℃ of drying baker, cross 20 mesh sieve granulate;
4) dried granule adds the low-substituted hydroxypropyl cellulose and the magnesium stearate of recipe quantity, mix homogeneously;
5) measure granule content, it is heavy to calculate designation card according to granule content, tabletting, and control tablet weight variation limit is ± 5%;
6) this product is carried out quality inspection;
7) finished product that is up to the standards is packed, promptly.
Embodiment 2
Prescription:
Fosfomycin calcium 2500g (by fosfomycin)
Lactose 200g
Microcrystalline Cellulose (in add) 400g
Microcrystalline Cellulose (adding) 400g
Low-substituted hydroxypropyl cellulose 1200g
Aspartame 20g
5% polyvinylpyrrolidone aqueous solution is an amount of
Magnesium stearate 60g
Make 10000
Preparation method:
1) get fosfomycin calcium and each adjuvant respectively, cross 100 mesh sieves respectively, standby;
2) get the fosfomycin calcium of recipe quantity, with the microcrystalline Cellulose that adds part in lactose, low-substituted hydroxypropyl cellulose, aspartame and the recipe quantity of recipe quantity, mix homogeneously;
3) with 5% polyvinylpyrrolidone aqueous solution system soft material, cross 20 mesh sieves and granulate, put drying in 75 ℃ of drying baker, cross 20 mesh sieve granulate;
4) dried granule adds the microcrystalline Cellulose and the magnesium stearate of recipe quantity Extra Section, and mix homogeneously is measured granule content;
5) it is heavy to calculate sheet according to granule content, tabletting, and control tablet weight variation limit is ± 5%;
6) this product is carried out quality inspection;
8) finished product that is up to the standards is packed, promptly.
Embodiment 3
Prescription:
Fosfomycin calcium 2500g (by fosfomycin)
Lactose 750g
Microcrystalline Cellulose 900g
Crospolyvinylpyrrolidone 300g
5% polyvinylpyrrolidone aqueous solution is an amount of
Magnesium stearate 55g
Make 10000
Preparation method:
1) get fosfomycin calcium and each adjuvant, cross 100 mesh sieves respectively, standby;
2) get the fosfomycin calcium of recipe quantity, mix with lactose, microcrystalline Cellulose, the crospolyvinylpyrrolidone of recipe quantity;
3) with 5% polyvinylpyrrolidone aqueous solution system soft material, cross 20 mesh sieves and granulate, put drying in 70 ℃ of drying baker, cross 20 mesh sieve granulate;
4) dried granule adds the magnesium stearate of recipe quantity, mix homogeneously;
5) measure granule content, it is heavy to calculate designation card according to granule content, tabletting, and control tablet weight variation limit is ± 5%;
6) this product is carried out quality inspection;
7) finished product that is up to the standards is packed, promptly.
Embodiment 4
Prescription:
Fosfomycin calcium 2500g (by fosfomycin)
Lactose 300g
Microcrystalline Cellulose 380g
Low-substituted hydroxypropyl cellulose 760g
Crospolyvinylpyrrolidone 300g
5% polyvinylpyrrolidone aqueous solution is an amount of
Magnesium stearate 55g
Make 10000
Preparation method:
With embodiment 3.
Embodiment 5
Prescription:
Fosfomycin calcium 2500g (by fosfomycin)
Lactose 200g
Microcrystalline Cellulose 1300g
Carboxymethyl starch is received 400g
Aspartame 20g
40% alcoholic solution is an amount of
Magnesium stearate 55g
Make 10000
Preparation method:
With embodiment 3.
Embodiment 6
Below, compare with commercially available common fosfomycin sheet, to further specify the superiority that the present invention develops product by the cumulative in vitro determination of dissolution rate.
The dissolution experimental technique is as follows: get this product, according to dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2005), with 0.1mol/L hydrochloric acid solution 1000ml is dissolution medium, rotating speed is that per minute 50 changes, operation in accordance with the law, through 5,10,15,20, in the time of 30 minutes, it is an amount of to get solution, makes the solution that every 1ml contains fosfomycin 100 μ g with the 0.1mol/L hydrochloric acid solution, filters, precision is measured subsequent filtrate 5ml, put in the 25ml measuring bottle, add freshly prepared Ammonium Persulfate 98.5 solution and (get Ammonium Persulfate 98.5 1g, add 15ml water, shake up, make dissolving) 1ml, with low amounts of water rinsing bottle wall, water-bath was boiled 10 minutes, take out, add 1% urea liquid 1ml, boiled again 10 minutes, take out, after being cooled to room temperature, adding 5% ammonium molybdate solution again (gets amine molybdate 10g, adds the sulfuric acid solution 100ml of 5mol/L, make dissolving, add water to 200ml, shaking up) 1.5ml and 0.5% sodium sulfite solution (get sodium sulfite 0.5g, add water 80ml and make dissolving, add p-methylaminophenol sulfate 0.2g again, sodium metabisulfite 30g, jolting makes dissolving, add water to 100ml, shake up) 1ml, thin up is to scale, room temperature was placed 20 minutes, as need testing solution; Other gets 10 of this product, the accurate title, decide, porphyrize, and precision takes by weighing in right amount (it is heavy to be equivalent to average sheet approximately), add the jolting of 0.1mol/L hydrochloric acid solution and make the fosfomycin calcium dissolving, and make the solution that contains fosfomycin 100 μ g among every 1ml approximately, and filtering, precision is measured subsequent filtrate 5ml, put in the 25ml measuring bottle, rise with the method operation from " adding freshly prepared ammonium persulfate solution 1ml, " according to the need testing solution compound method, make contrast solution with low amounts of water rinsing bottle wall.Get above-mentioned two kinds of solution, do blank with water, according to spectrophotography (two appendix IV of Chinese Pharmacopoeia version in 2005 B), the place measures trap respectively at the 650nm wavelength, calculates every stripping quantity with the ratio meter of the two trap.The average dissolution of each embodiment sample and commercially available each time point of sample sees Table 1, and the accumulation stripping curve is seen Fig. 1.
Average dissolution (%) result (n=6) of each embodiment sample of table 1 and commercially available each time point of sample
| Time (min) | 5 | 10 | 15 | 20 | 30 |
| Commercially available sample | 29 | 36.7 | 44.8 | 65 | 77.9 |
| Embodiment 1 | 84 | 98.5 | 99.6 | 99.4 | 98.9 |
| Embodiment 2 | 81.7 | 85.2 | 93.9 | 98.2 | 98.6 |
| Embodiment 3 | 75.6 | 88 | 94.5 | 98.4 | 99 |
| Embodiment 4 | 82.1 | 97.4 | 98.8 | 99 | 99.2 |
| Embodiment 5 | 80.9 | 94.5 | 98 | 98.5 | 99.1 |
By form improvement and optimal process, with FOM-Ca and the disintegrant of pharmaceutically commonly using, mix according to a certain percentage, make the Fosfocina calcium disperser agent, combine the advantage of tablet and liquid preparation, and avoid its shortcoming. Have that good dispersing state, disintegration time are short, drug-eluting rapidly, absorb fast, the advantages such as bioavilability is high, bad reaction is few, taking convenience, good stability, can swallow, chew contain suck or in water, disperse after with fruit juice, milk and clothes, the patient of especially suitable the elderly, children, dysphagia.
Claims (2)
1, a kind of Fosfocina calcium disperser, wherein, fosfomycin calcium 2500g (pressing fosfomycin calculates), pregelatinized Starch 500g, lactose 350g, glue connection polyvinylpyrrolidone 300g, low-substituted hydroxypropyl cellulose 350g, magnesium stearate 50g as system soft material solution, makes 10000 with 40% alcoholic solution; Perhaps, fosfomycin calcium 2500g (pressing fosfomycin calculates), lactose 200g, microcrystalline Cellulose (in add) 400g, microcrystalline Cellulose (adding) 400g, low-substituted hydroxypropyl cellulose 1200g, magnesium stearate 60g, aspartame 20g as system soft material solution, makes 10000 with 5% polyvinylpyrrolidone aqueous solution; Perhaps, fosfomycin calcium 2500g (pressing fosfomycin calculates), lactose 750g, microcrystalline Cellulose 900g, crospolyvinylpyrrolidone 300g, magnesium stearate 55g as system soft material solution, makes 10000 with 5% polyvinylpyrrolidone aqueous solution; Perhaps, fosfomycin calcium 2500g (pressing fosfomycin calculates), lactose 300g, microcrystalline Cellulose 380g, low-substituted hydroxypropyl cellulose 760g, crospolyvinylpyrrolidone 300g, magnesium stearate 55g as system soft material solution, makes 10000 with 5% polyvinylpyrrolidone aqueous solution; Perhaps, fosfomycin calcium 2500g (pressing fosfomycin calculates), lactose 200g, microcrystalline Cellulose 1300g, carboxymethyl starch sodium 400g, aspartame 20g, magnesium stearate 55g as system soft material solution, makes 10000 with 40% alcoholic solution.
2, the described Fosfocina calcium disperser of claim 1 is used for the treatment of application in the medicine of intestinal infection, urinary tract infection, Helicobacter pylori infection, hordeolum, hordeolum, otitis media, nasal sinusitis or dacryocystisis in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101058918A CN100339084C (en) | 2005-10-09 | 2005-10-09 | Fosfocina calcium disperser, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101058918A CN100339084C (en) | 2005-10-09 | 2005-10-09 | Fosfocina calcium disperser, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1757393A CN1757393A (en) | 2006-04-12 |
| CN100339084C true CN100339084C (en) | 2007-09-26 |
Family
ID=36703062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101058918A Expired - Fee Related CN100339084C (en) | 2005-10-09 | 2005-10-09 | Fosfocina calcium disperser, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100339084C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101623273B (en) * | 2009-08-14 | 2011-09-28 | 山东罗欣药业股份有限公司 | Rifaximin medicament combination dispersible tablet and preparation method thereof |
| CN102784118A (en) * | 2012-08-23 | 2012-11-21 | 海南卫康制药(潜山)有限公司 | Fosfomycin calcium composition freeze-dried orally disintegrating tablets and preparation method thereof |
| CN104510720A (en) * | 2014-12-25 | 2015-04-15 | 云南昊邦制药有限公司 | 2-(alpha-hydroxypentyl) benzoate dispersible tablet and preparation method thereof |
| CN105582060B (en) * | 2016-03-02 | 2019-11-05 | 西华大学 | Pharmaceutical composition for preventing and treating respiratory system diseases and preparation method and application thereof |
| CN109010306A (en) * | 2018-10-25 | 2018-12-18 | 安徽鼎旺医药有限公司 | A kind of preparation method of fosfomycin calcium capsule |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE893312A (en) * | 1981-06-04 | 1982-09-16 | Crinos Industria Farmaco | ANTIBIOTIC COMPOSITION FOR THE DELIVERY OF PHOSPHOMYCIN IN THE FORM OF SLOW-DISSOLVING TABLETS |
| CN1273824A (en) * | 1999-05-13 | 2000-11-22 | 沈阳药科大学 | Exterior-applied medicine containing phosphonomycin calcium and its application |
-
2005
- 2005-10-09 CN CNB2005101058918A patent/CN100339084C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE893312A (en) * | 1981-06-04 | 1982-09-16 | Crinos Industria Farmaco | ANTIBIOTIC COMPOSITION FOR THE DELIVERY OF PHOSPHOMYCIN IN THE FORM OF SLOW-DISSOLVING TABLETS |
| CN1273824A (en) * | 1999-05-13 | 2000-11-22 | 沈阳药科大学 | Exterior-applied medicine containing phosphonomycin calcium and its application |
Non-Patent Citations (1)
| Title |
|---|
| 应用HPMC提高磷霉素钙片的质量 郑波等，中国药学杂志，第32卷第5期 1997 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1757393A (en) | 2006-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1213754C (en) | Beta-carboline pharmaceutical compositions | |
| CN1174745C (en) | Use of coating as taste masking agent for oral preparation | |
| CN1297274C (en) | Medical composition | |
| CN1946403A (en) | Use of flibanserin in the treatment of premenstrual and other female sexual disorders | |
| CN1494419A (en) | Preparations quickly disintegrating in oral cavity | |
| CN103429223A (en) | Orally dispersible tablet | |
| CN1864672A (en) | A solid dispersion of ambroxol hydrochloride and composition thereof | |
| CN100339084C (en) | Fosfocina calcium disperser, and its prepn. method | |
| CN101056658A (en) | Oral preparation having improved bioavailability | |
| CN1105240A (en) | Pharmaceutical composition | |
| CN1939305A (en) | Cephalofruxin ester liposome, its preparation and medicinal composition containing it | |
| CN1853631A (en) | Fast disintegrant containing paroxetine | |
| CN101032489A (en) | Cefprozil dispersible table and the preparing method | |
| CN1903182A (en) | Miniaturization sarpogrelate hydrochloride oral drug-giving preparation | |
| CN1799543A (en) | Telmisartan dispersible tablet and its preparation method | |
| CN1241566C (en) | Cilostazol solid dispersion and its method for preparing tablet | |
| CN1823800A (en) | Oral composition containing spiramycin capabile of masking bitter taster | |
| CN1537005A (en) | Amorphous cefditoren pivoxil composition and process for producing the same | |
| CN1319533C (en) | Cefetamet pivoxil hydrochloride dispersion dispersion tablets and preparation method | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
| KR20070034002A (en) | Solid pharmaceutical preparations | |
| CN1919185A (en) | Compound ammonium glycyrrhizinato S dispersed tablet and its preparing process | |
| CN1682739A (en) | Cefadroxil dry suspension and preparing method | |
| CN1175811C (en) | Slow-releasing Anixitan tablet | |
| CN1582927A (en) | Oral disintegrants of nimodipine and their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hefei Tianyi Institute of Biological Technology Assignor: Wang Wanyu Contract record no.: 2010340000070 Denomination of invention: Fosfocina calcium disperser, and its prepn. method Granted publication date: 20070926 License type: Exclusive License Open date: 20060412 Record date: 20100427 |
|
| DD01 | Delivery of document by public notice |
Addressee: Wang Wanyu Document name: Notification to Pay the Fees |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070926 Termination date: 20161009 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |